Liquidia Corporation Common Stock LQDA

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

• Zacks Investment Research 1 oct

  Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

  A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.

  

• Zacks Investment Research 1 oct

  UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

  United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement.

  

• Zacks Investment Research 11 sept

  LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

  Liquidia's lead drug Yutrepia has gained significant market traction with over 5,000 patients started on therapy as of July 2026, but the stock has underperformed due to heavy reliance on a single product, ongoing patent litigation with United Therapeutics, competitive pressures, and rising R&D costs. Analysts recommend avoiding the stock due to an unfavorable risk-reward profile.

  

• Zacks Investment Research 31 ago

  Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

  Liquidia Corporation's lead drug Yutrepia generated $300.3 million in first-half 2026 sales, driving the company's fourth consecutive profitable quarter. However, the pulmonary arterial hypertension (PAH) market faces intense competition from established therapies and pipeline candidates from United Therapeutics and Insmed. Liquidia plans to expand Yutrepia into additional indications including COPD, IPF, PPF, and Raynaud's phenomenon to sustain long-term growth.

  

• Zacks Investment Research 31 ago

  Is the Options Market Predicting a Spike in Liquidia Stock?

  Liquidia Corporation (LQDA) is drawing attention from options traders due to high implied volatility in its Jan 15, 2027 $22.50 Call options, suggesting investors expect a significant price movement. The company holds a Zacks Rank #3 (Hold) rating in the Medical - Biomedical and Genetics industry, with analyst consensus estimates for the current quarter recently improving from 74 cents to 82 cents per share. Options traders may be positioning to sell premium and capture decay, betting the stock won't move as dramatically as the implied volatility suggests.